Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
Visit archive to view all company announcements
22 October 2015
9M sales and profit in line with August expectations; full-year outlook narrowed
06 August 2015
Full-year profit outlook maintained. Sales growth expectations revised
23 April 2015
Q1 in line with expectations; 2015 outlook adjusted for currencies
27 March 2015
Pursuant to company announcement no. 11, 2015, a reduction of the company’s B common stock by DKK 13,400,000 via cancellation of 6,700,000 treasury B stocks was adopted at the Annual Shareholders’ Meeting of Novozymes A/S on February 25, 2015.
25 February 2015
Today Novozymes A/S held its Annual Shareholders’ Meeting.
29 January 2015
On February 2, 2015, Novozymes will initiate a stock buyback program as announced in Company announcement No. 1 of January 20, 2015.
20 January 2015
Positive outlook for 2015. Long-term targets updated
23 October 2014
Increased expectations for full-year profit. 2014 sales growth on track
14 August 2014
First-half performance in line with expectations; full-year profit outlook increased
24 April 2014
Strong Q1 performance; full-year profit outlook increased
Paras Biopharmaceuticals partners with Novozymes in a feasibility study using VELTIS® technology to develop an improved version of a leading osteoporosis treatment.
November 24 2015
Scientific breakthroughs and new products are expected to significantly increase demand for microbial technologies over the next 10 years. Microbes can increase crop yields and complement or replace agricultural chemicals and fertilizers.
November 17 2015
Employees motivated by finding biological solutions to global challenges.
October 30 2015
| Copyright © 2015 Novozymes. All Rights Reserved.